The Pharmaceutical Research and Manufacturers of America has created an advisory board of R&D executives that the trade association hopes will guide it back to a future in which pharmaceutical companies were seen by the public, politicians and the medical community as scientific organizations driving the advancement of medicine.

The $190 million PhRMA has spent on lobbying Congress over the last decade - plus hundreds of millions in coordinated lobbying by PhRMA members - have made it a powerhouse in the often brutal fights over legislation and policy affecting the industry.